Table 1 Baseline characteristics of the study population
Variables | NOAF (n = 30) | Without NOAF (n = 281) | P value |
|---|---|---|---|
Age, years | 82.43 ± 9.21 | 73.37 ± 10.31 | < 0.001 |
Male, n (%) | 23 (76.67) | 229 (81.49) | 0.322 |
STEMI, n (%) | 19 (63.33) | 175 (62.78) | 0.925 |
HT, n (%) | 18 (60) | 156 (55.52) | 0.761 |
DM, n (%) | 9 (30) | 95 (33.81) | 0.546 |
History of MI, n (%) | 8 (26.67) | 50 (17.79) | 0.179 |
History of PCI, n (%) | 5 (16.67) | 39 (13.88) | 0.159 |
History of CABG, n (%) | 2 (6.67) | 7 (2.49) | 0.192 |
History of CHF, n (%) | 2 (6.67) | 29 (10.32) | 0.564 |
History of stroke, n (%) | 6 (20) | 38 (13.52) | 0.218 |
Current smoker, n (%) | 16 (53.33) | 166 (59.07) | 0.45 |
BMI, kg/m2 | 24.33 ± 2.39 | 26.19 ± 3.07 | 0.061 |
SBP, mmHg | 122.37 ± 22.82 | 126.49 ± 19.83 | 0.172 |
DBP, mmHg | 66.37 ± 12.41 | 65.49 ± 13.29 | 0.223 |
HR at admission, bpm | 74 ± 13.6 | 78.56 ± 12.49 | 0.074 |
IRA | Â | Â | Â |
 RCA, n (%) | 8 (26.67) | 92 (32.74) | 0.304 |
 LAD, n (%) | 13 (43.33) | 123 (43.77) | 0.932 |
 LCX, n (%) | 7 (23.33) | 57 (20.28) | 0.21 |
Killip class | Â | Â | Â |
 I, n (%) | 7 (23.33) | 118 (41.99) | 0.003 |
 II, n (%) | 13 (43.33) | 132 (46.98) | 0.317 |
 III, n (%) | 8 (26.67) | 22 (7.83) | 0.001 |
 IV, n (%) | 2 (6.67) | 9 (3.2) | 0.135 |
WBC, 109/L | 9.88 ± 2.83 | 10.34 ± 3.42 | 0.543 |
Hb, g/L | 135.78 ± 20.36 | 139.74 ± 19.18 | 0.263 |
PLT, 109/L | 210.2 ± 58.74 | 223.17 ± 65.39 | 0.053 |
HbAlc, % | 6.1 (5.85–7.4) | 6.3 (5.6–7.2) | 0.684 |
ESR, mm/h | 11.3 (5.55–24.78) | 8.1 (4.08–15.1) | 0.084 |
Hs-CRP, mg/L | 28.03 (2.64–91.38) | 5.2 (2.21–19.04) | 0.003 |
D-dimer, mg/L FEU | 0.35 (0.22–0.89) | 0.29 (0.2–0.61) | 0.144 |
CK-MB, ng/ml | 18.54 (9.6–100.44) | 35.29 (6.2–133.41) | 0.677 |
CTnI, ng/ml | 17.22 (7.11–106.3) | 30.01 (6.32–109.71) | 0.747 |
TC, mmol/L | 4.3 ± 1.02 | 4.49 ± 1.11 | 0.169 |
TG, mmol/L | 1.37 (0.92–1.77) | 1.41 (1.01–2.1) | 0.171 |
LDL-C, mmol/L | 2.67 ± 1.18 | 3.03 ± 1.16 | 0.079 |
HDL-C, mmol/L | 0.97 ± 0.24 | 0.96 ± 0.25 | 0.994 |
LP(a), mg/dl | 16.4 (8.51–23.6) | 14.04 (8.43–29.82) | 0.961 |
BNP, pg/ml | 384 (184–886.41) | 151.3 (72.56–278.53) | < 0.001 |
SCR, µmol/L | 68.1 (56.1–95.47) | 67.42 (58.77–81.39) | 0.948 |
eGFR, ml/min/1.73 m2 | 99.37 ± 32.51 | 107.24 ± 30.57 | 0.125 |
SUA, umol/L | 397.81 ± 141.27 | 384.19 ± 103.99 | 0.211 |
LVEF, % | 53.6 (40.72–63.19) | 61.4 (48.79–66.3) | 0.023 |
LVESd, mm | 34 (30.1–38.1) | 32 (28–39) | 0.109 |
LVEDd, mm | 48.4 (44.91–54.2) | 48 (44–52) | 0.362 |
LAD,mm | 38.1 (34.7–42.59) | 35.2 (33.2–38.4) | 0.031 |
Medications | Â | Â | Â |
 ACEI/ARB, n (%) | 5 (16.67) | 107 (38.08) | 0.046 |
 Beta blocker, n (%) | 14 (46.67) | 186 (66.19) | 0.069 |
 Statin, n (%) | 28 (93.33) | 272 (96.78) | 0.367 |
IABP, n (%) | 5 (16.67) | 28 (9.96) | 0.055 |
CHADS2 score | 2 (1–3) | 1 (1–2) | 0.019 |
CHA2DS2-VASc score | 4 (3–5) | 3 (2–4) | 0.001 |
In-hospital mortality, n (%) | 3 (10) | 3 (1.06) |  < 0.001 |